
Researchers reviewed evidence linking SLC transporters to neurological disorders. Advances in drug discovery and gene therapy are expanding opportunities to target these proteins in epilepsy, autism, Alzheimer's, and Parkinson's disease.
Technology Networks
Original source
target
Check live status on DownRightNow
